The Trump administration has escalated its push to reshape global pharmaceutical pricing, opening a formal trade investigation into Germany over what it characterizes as persistent underpayment for innovative drugs — the latest move in a broader campaign to reduce the share of research and development costs borne by American patients.
Here are five things to know:
1. The U.S. trade representative initiated a Section 301 investigation.
U.S. Trade Representative Jamieson Greer launched the investigation under Section 301 of the Trade Act of 1974, according to a June 18 news release. It allows the U.S. to impose tariffs or other trade remedies in response to foreign practices deemed unreasonable, discriminatory or harmful to U.S. commerce. The probe will examine whether Germany’s pharmaceutical pricing policies — including confidential supplemental discounts and mandatory variable-rate rebates — place a disproportionate share of global drug R&D costs on the U.S. The USTR has requested formal consultations with the German government. Written comments are due Aug. 10, and a public hearing is scheduled for Sept. 22.
2. The administration framed it as a fair-share argument.
“President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,” Mr. Greer said in the release. He cited reports that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals as a “serious step backwards.” HHS Secretary Robert F. Kennedy Jr. added that “fighting the war against disease is a shared burden across wealthy nations.” The administration pointed to a pharmaceutical pricing arrangement with the U.K. announced April 2 as a model Germany should follow.
3. The probe is rooted in a May 2025 executive order.
President Donald Trump directed the USTR to take “all necessary and appropriate action” against foreign countries whose pricing practices force American patients to subsidize global drug innovation. That order also authorized the commerce secretary and the USTR to pursue trade actions against countries keeping drug prices artificially low — and explicitly revived the most-favored-nation pricing concept the administration has since pursued through bilateral deals with Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk and others.
4. Section 301 has been used repeatedly.
The USTR initiated 60 Section 301 investigations in March; it is widely seen as legal groundwork for replacing the expiring Section 122 tariff with more durable trade authority, with proposed duty rates of 10% to 12.5% depending on the country’s trade practices. The USTR also concluded a Section 301 determination against Brazil in June over pharmaceutical-related trade practices.
5. The probe adds pressure to an already shifting drug pricing landscape.
Drug pricing in 2026 is being reshaped simultaneously by Medicare price negotiation, TrumpRx most-favored-nation deals and now international trade enforcement. For health system pharmacy leaders, the implications of broader manufacturer pricing adjustments, whether driven by domestic policy or international trade pressure, feed directly into drug cost projections and shortage risk, particularly for injectable generics and low-margin medications already prone to supply disruption.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
